
Valeant announces expanded discounts for Nitropress and Isuprel
pharmafile | May 17, 2016 | News story | Manufacturing and Production, Sales and Marketing | Isuprel, Nitropress, Valeant, discounts
Valeant Pharmaceuticals (NYSE: VRX) has stepped up its public relations campaign with an announcement of expanded discounts for Nitropress (nitroprusside) and Isuprel (isoproterenol).
These drugs, for blood pressure and heart issues respectively, were subject to major price rises when Valeant acquired them. Due to public and governmental pressures, the company is seeking to change its image and be seen to be adopting a responsible pricing policy.
Under this new programme just announced, all hospitals in the US will be eligible for a rebate of at least 10%, with rebates totalling 20%, 30% or 40% based on volume purchased during a calendar quarter for hospitals that purchase large volumes of the relevant drug. This rebate programme is effective immediately.
Valeant has also indicated that there will be no further price rises or reductions to the discount levels.
New chairman and CEO, Joseph Papa, says: “Under this new programme, the discounts we previously implemented for Nitropress and Isuprel will be simplified and more accessible. I understand the concerns our partners in the health care community have had about the pricing of these drugs, and we want to ensure hospitals and patients can get the drugs they need.
“I also want to thank the Senate Committee on Aging and the House Committee on Oversight and Government Reform for the attention they have brought to this issue, and specifically to gaps they identified in the previous programme. We are committed to getting this right.”
Sean Murray
Related Content

FDA rejects Valeant plaque psoriasis lotion over pharmacokinetic concerns
Beleaguered pharma firm Valeant has come up against another bump in the road as its …

Top Ten most popular articles on Pharmafile.com this week
It’s been a week in which one of the largest pharmaceutical takeovers in history took …

Valeant seeks clean slate with rebrand, new company name
In the latest attempt to reverse its ailing fortunes and distance itself from its polluted …






